I agree that this site is using cookies. You can find further informations here.
X
Gonzalez Barca, Eva
283  results:
Search for persons X
?
1

Extranodal natural killer/T‐cell lymphoma nasal type in a w..:

Gonzalez Barca, Eva ; Tomás‐Roca, Laura ; Esteve, Anna...
American Journal of Hematology.  98 (2023)  6 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
2

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATI..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
HemaSphere.  7 (2023)  S3 - p. e4580941 , 2023
Link: https://doi.org/10.1097/..
 
?
3

Developing New Strategies for Relapsed/Refractory Diffuse L..:

Gonzalez Barca, Eva
Journal of Clinical Medicine.  12 (2023)  23 - p. 7376 , 2023
Link: https://doi.org/10.3390/..
 
?
4

EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related ..:

Navarro Matilla, Belén ; Onteniente Gomis, Mª del Mar ; Pujol Vallverdú, Ramon M....
JEADV Clinical Practice.  1 (2022)  4 - p. 438-449 , 2022
Link: https://doi.org/10.1002/..
 
?
5

Role of Bispecific Antibodies in Relapsed/Refractory Diffus..:

González Barca, Eva
Frontiers in Immunology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
6

MCL-113: IBRORS-MCL Study: A Spanish Retrospective and Obse..:

Sancho, Juan Manuel ; Marín, Ana ; Fernández, Silvia...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S258-S259 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Are Biosimilars the Future of Oncology and Haematology?:

Zinzani, Pier Luigi ; Dreyling, Martin ; Gradishar, William...
Drugs.  79 (2019)  15 - p. 1609-1624 , 2019
Link: https://doi.org/10.1007/..
 
?
8

CD 30-positive transformed follicular lymphoma: two case re..:

Montes-Moreno, Santiago ; Climent, Fina ; González de Villambrosía, Sonia...
Histopathology.  67 (2015)  6 - p. 918-922 , 2015
Link: https://doi.org/10.1111/..
 
?
9

POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitam..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S206 , 2023
Link: https://doi.org/10.1016/..
 
?
10

POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S206 , 2023
Link: https://doi.org/10.1016/..
 
?
11

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Pa..:

Duell, Johannes ; Abrisqueta, Pau ; Andre, Marc...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S433-S434 , 2023
Link: https://doi.org/10.1016/..
 
?
12

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALI..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
HemaSphere.  7 (2023)  S3 - p. e7389505 , 2023
Link: https://doi.org/10.1097/..
 
?
13

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenal..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S436-S437 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymph..:

Soumerai, Jacob D. ; Opat, Stephen ; Cheah, Chan Y....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S140 , 2022
Link: https://doi.org/10.1016/..
 
?
15

CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 In..:

Soumerai, Jacob D. ; Opat, Stephen ; Cheah, Chan Y....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S267-S268 , 2022
Link: https://doi.org/10.1016/..
 
1-15